PK/PD and effect of T-5224 on HIV-1 transcriptional activity in an HIV-1-mouse model
Active Awarded Last action
- Contract number
- 75N93024F00001
- Awardee
-
Board Of Regents Of The University Of Nebraska UEI G15AG3BLLMH4 Part of Board Of Regents Of University Of Nebraska
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $358,733
Award facts
- Opportunity
-
- Interventional Agents Chemistry Services Pre-Solicitation · 75N93024R00002 · Posted Nov 3, 2023
- Contract value 30% obligated
- $1,207,737.00 Current and potential, with all options
- Completion date 97% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Omaha, NE 68198, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $358,733 | |
| Other Administrative Action | $0 | |
| Original award | $849,004 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1.21 million delivery order to the University of Nebraska Medical Center (UNMC) on August 1, 2024, for preclinical services supporting HIV therapeutics research. The specific focus is pharmacokinetic/pharmacodynamic (PK/PD) evaluation and assessment of T-5224's effect on HIV-1 transcriptional activity using an HIV-1-mouse model. This delivery order is issued under the "Preclinical Services for HIV Therapeutics" master indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The work will be performed in Omaha, Nebraska, with an ultimate completion date of November 30, 2026. No small business set-aside designation applies to this contract, and it is structured as a cost-plus-no-fee arrangement, indicating reimbursement of allowable costs without profit markup.
UNMC, operating under the Board of Regents of the University of Nebraska, is well-positioned to execute this award given its extensive experience conducting biomedical research and drug development support services for federal agencies. The institution maintains substantial grant funding from NIAID and other National Institutes of Health components for HIV-related research, including recent awards for pediatric HIV formulation development. UNMC's demonstrated capabilities across infectious disease research, preclinical laboratory services, and animal model studies align directly with the contract requirements for evaluating novel HIV therapeutic candidates through rigorous pharmacological and virological assessments.
Quick answers
Who was awarded contract 75N93024F00001?
75N93024F00001 was awarded to Board Of Regents Of The University Of Nebraska by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 1, 2024.
How much is contract 75N93024F00001 worth?
The government has obligated $358,733 on 75N93024F00001. Its current value, with exercised options, is $1,207,737.
Is contract 75N93024F00001 an order under another contract?
Yes. 75N93024F00001 is a delivery order under 75N93021D00006, an indefinite delivery contract, on Preclinical Services for HIV Therapeutics.
Was contract 75N93024F00001 competed?
The extent of competition for 75N93024F00001 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award